目的 克隆人 B7.1全长 c DNA及构建相应的逆转录病毒表达载体。 方法 应用逆转录多聚酶链反应从人 B淋巴瘤细胞系 Raji中克隆 B7.1全长 c DNA ,再将 c DNA插入到质粒 p Bluescript中 ,经自动荧光测序证实无误后 ,再通过定向克隆构建...目的 克隆人 B7.1全长 c DNA及构建相应的逆转录病毒表达载体。 方法 应用逆转录多聚酶链反应从人 B淋巴瘤细胞系 Raji中克隆 B7.1全长 c DNA ,再将 c DNA插入到质粒 p Bluescript中 ,经自动荧光测序证实无误后 ,再通过定向克隆构建相应的逆转录病毒表达载体 PL XSNh B7。 结果 逆转录多聚酶链反应扩增产物长度与预期的 889bp一致 ;用 M13正、反向引物进行荧光测序证实 ,克隆出的序列与 Gen Bank的 B7.1c DNA序列完全一致 ;人 B7.1全长 c DNA被成功地插入到质粒 PL XSN中。 结论 人 B7.1全长 c DNA的克隆及相应逆转录病毒表达载体的构建为今后应用 B7.1进行肿瘤免疫基因治疗提供了可能性。展开更多
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We t...Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375 mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥ 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.展开更多
文摘Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375 mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥ 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
